Menu
01. Doctor Overview

Doctor Overview

Dr. Michael Keppen is a medical oncologist and hematologist at the Sanford Cancer Center, serving as the Director of the Sanford Lung Tumor Program. Dr. Keppen also teaches as a clinical professor at Sanford USD School of Medicine. Additionally, Dr. Keppen works for theNational Cancer InstituteCommunity Oncology Research Program.

Dr. Keppen has been a practicing oncologist for over two decades, with a particular specialty in lung cancer. His focus is to improve cancer survivorship overall, providing customized care for his patients to improve survival and quality of life. To help improve survivorship, Dr. Keppen is actively involved in cancer research andclinical trials, with several studies he’s collaborated on focused around improvingchemotherapy drugs.

02. Fast Facts

Doctor Fast Facts

Main Specialty:Hematology-Oncology

Other Interests & Specialties:Oncology, internal medicine, lung cancer, chronic myeloid leukemia, epidemiology, myeloma, metastatic breast cancer, blood cancer, lymphoma and palliative care.

Certifications, Awards & Accolades:美国内科医学委员会认证in Medical Oncology, American Board of Internal Medicine Certification in Hematology, member of American Society of Clinical Oncology (ASCO)

Education & Experience:

  • Fellowship at the University of Oklahoma Health Sciences Center
  • Residency at the University of Oklahoma Health Sciences Center
  • Medical Degree from the Sanford School of Medicine at the University of South Dakota
03. Publications

Publications

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.Investigational New Drugs. April 2014;32(2):295-302. doi:10.1007/s10637-013-9999-7

b化疗原则reast, prostate, colon and lung cancer.South Dakota Medicine. 2010; Spec No:52-6.

Photo of Dr. Michael Keppen

Get Help Contacting Dr. Michael Keppen

Where Should We Overnight Your Free Guide?



    Privacy policy:All information is secure and will never be released

    TRUSTe
    Baidu